Form 4: Director Kathryn Zoon Trades Emergent BioSolutions Stock

Director Kathryn C. Zoon of Emergent BioSolutions Inc. (EBS) reported transactions involving restricted stock units and stock options, including the acquisition of RSUs and the sale of shares to cover tax obligations.

Summary

• Kathryn C. Zoon, a Director at Emergent BioSolutions Inc. (EBS), acquired 25,344 restricted stock units (RSUs) on April 30, 2026, as an annual grant for board and committee service. These RSUs vest one year from the grant date, provided she remains a director.
• On May 1, 2026, Zoon sold a total of 17,202 shares of common stock. This included 16,145 shares sold at a weighted average price between $7.77 and $8.70, and 1,057 shares sold at a weighted average price between $8.79 and $8.99.
• These sales were executed as part of a Rule 10b5-1 trading plan established on May 16, 2025, specifically to satisfy tax obligations arising from the vesting of RSUs on April 29, 2026.
• Additionally, Zoon acquired 11,296 stock options on April 30, 2026, with an exercise price of $7.99. These options are also for board and committee service and will vest on the one-year anniversary of the grant date, contingent on her continued directorship.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the acquisition of equity awards is positive, the sale of a significant number of shares by a director, even under a pre-planned 10b5-1, can introduce some negative sentiment.

Positives

• Acquisition of 25,344 RSUs and 11,296 stock options indicates continued equity-based compensation for director services.
• The sale of shares was conducted under a pre-established Rule 10b5-1 trading plan, demonstrating adherence to compliance and risk management protocols for insider transactions.
• The sales were specifically to cover tax obligations, a common and expected reason for insider stock sales.

Negatives

• A significant number of shares (17,202) were sold by a director, which could be perceived negatively by the market, despite being part of a pre-planned strategy.
• The sale prices for the shares were relatively low, with weighted averages in the $7.77-$8.70 and $8.79-$8.99 ranges, suggesting sales occurred at a depressed market value.

Risks

• Potential for negative market perception due to the sale of a substantial number of shares by a director, even if executed under a 10b5-1 plan.
• The vesting of RSUs and stock options is contingent on the reporting person remaining a director, introducing a risk of forfeiture if directorship changes.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales were executed pursuant to a Rule 10b5-1 trading plan for the purpose of satisfying tax obligations relating to the vesting of RSUs.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a director of Emergent BioSolutions (EBS) is a common practice to manage personal finances and tax liabilities while mitigating insider trading concerns. The specific timing and prices of these transactions may reflect market conditions for EBS during early May 2026.

Stakeholder Impact

• Shareholders: May observe the director's stock sales, potentially influencing short-term trading sentiment, though the pre-planned nature mitigates insider trading concerns.
• Employees: The transactions do not directly impact employee compensation or benefits but reflect the company's equity compensation structure for directors.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Vesting of remaining RSUs and stock options, subject to continued directorship.
• Potential future transactions under the Rule 10b5-1 plan if applicable.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Emergent BioSolutions, EBS, Director Transactions, Rule 10b5-1, Beneficial Ownership